Pharmacogenetic algorithm for predicting daily dose of warfarin in Caucasian patients of Czech origin
Author:
Tomek Aleš12, Šrámková Tereza1, Kaplan Vojtěch2, Lacinová Zuzana2, Kumstýřová Simona2, Šrámek Martin1, Olšerová Anna1, Janský Petr1, Kolářová Tereza2, Neumann Jiří3, Schwabová Jaroslava Paulasová1, Maťoška Václav2
Affiliation:
1. Department of Neurology , 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital , V Uvalu 84 , Prague , Czech Republic 2. Department of Clinical Biochemistry, Haematology and Immunology, Laboratory of Molecular Genetics , Hospital Na Homolce , Prague , Czech Republic 3. Department of Neurology , Chomutov Regional Hospital , Chomutov , Czech Republic
Abstract
Abstract
Objectives
Warfarin use is limited by a low therapeutic index and significant interindividual variability of the daily dose. The most important factor predicting daily warfarin dose is individual genotype, polymorphisms of genes CYP2C9 (warfarin metabolism) and VKORC1 (sensitivity for warfarin). Algorithms using clinical and genetic variables could predict the daily dose before the initiation of therapy. The aim of this study was to develop and validate an algorithm for the prediction of warfarin daily dose in Czech patients.
Methods
Detailed clinical data of patients with known and stable warfarin daily dose were collected. All patients were genotyped for polymorphisms in genes CYP2C9 and VKORC1.
Results
Included patients were divided into derivation (n=175) and validation (n=223) cohorts. The final algorithm includes the following variables: Age, height, weight, treatment with amiodarone and presence of variant alleles of genes CYP2C9 and VKORC1. The adjusted coefficient of determination is 72.4% in the derivation and 62.3% in the validation cohort (p<0.001).
Conclusions
Our validated algorithm for warfarin daily dose prediction in our Czech cohort had higher precision than other currently published algorithms. Pharmacogenetics of warfarin has the potential in the clinical practice in specialized centers.
Publisher
Walter de Gruyter GmbH
Subject
Pharmacology (medical)
Reference16 articles.
1. Tomek, A, Matoska, V, Eisert, C, Serebruany, VL. Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations. Am J Therapeut 2011;18:55–66. https://doi.org/10.1097/mjt.0b013e3181cea0cd. 2. Tomek, A, Kolářová, T, Lacinová, Z, Martinková, S, Šrámek, M, Šarbochová, I, et al.. Přesnost farmakogenetických algoritmů pro výpočet denní dávky warfarinu. Ces Slov Neurol Neurochir 2013;76/109:596–602. 3. Higashi, M, Veenstra, DL, Kondo, LM, Wittkovsky, AK, Srinouanprachanhto, SL, Farin, FM et al.. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002;287:1690–8. https://doi.org/10.1001/jama.287.13.1690. 4. International Warfarin Pharmacogenetics Consortium, Klein, TE, Altman, RB, Eriksson, N, Gage, BF, Kimmel, SE, Lee, MT, et al.. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753–64. https://doi.org/10.1056/NEJMoa0809329. 5. Sconce, E, Khan, TI, Wynne, HA, Avery, P, Monkhouse, L, King, BP, et al.. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329–33. https://doi.org/10.1182/blood-2005-03-1108.
|
|